Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.18938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of a TNIK-CDK9 axis as a targetable strategy for platinum-resistant ovarian cancer.
Mol Cancer Ther
January 2025
University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
Up to 90% of high-grade serous ovarian cancer (HGSC) patients will develop resistance to platinum-based chemotherapy, posing substantial therapeutic challenges due to a lack of universally druggable targets. Leveraging BenevolentAI's AI-driven approach to target discovery, we screened potential AI-predicted therapeutic targets mapped to unapproved tool compounds in patient-derived 3D models. This identified TNIK, which is modulated by NCB-0846, as a novel target for platinum-resistant HGSC.
View Article and Find Full Text PDFThe C-Alkene Triol Conundrum: Structural Characterization and Quantitation of Isoprene-Derived CHO Reactive Uptake Products.
Environ Sci Technol Lett
September 2022
Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States 27599.
2-Methyltetrols and CHO compounds, referred to as "C-alkene triols," are chemical tracers used to estimate isoprene-derived epoxydiol (IEPOX) contributions to atmospheric PM. For nearly two decades, "C-alkene triol" molecular structures and PM mass contributions remain uncertain, and their origin as analytical artifacts is unclear. Thus, we synthesized CHO reactive uptake product candidates (3-methyltetrahydrofuran-2,4-diol and 3-methylenebutane-1,2,4-triol) and investigated their behavior under conventional gas chromatography/electron impact-mass spectrometry (GC/EI-MS) with prior trimethylsilylation and, in parallel, by non-destructive hydrophilic-interaction liquid chromatography coupled with electrospray ionization interfaced to high-resolution quadrupole-time-of-flight mass spectrometry (HILIC/ESI-HR-QTOFMS).
View Article and Find Full Text PDFIdentification of mitophagy-related key genes and their correlation with immune cell infiltration in acute myocardial infarction via bioinformatics analysis.
Front Cardiovasc Med
January 2025
Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
Background: Acute myocardial infarction (AMI), a subset of acute coronary syndrome, remains the major cause of mortality worldwide. Mitochondrial dysfunction is critically involved in AMI progression, and mitophagy plays a vital role in eliminating damaged mitochondria. This study aimed to explore mitophagy-related biomarkers and their potential molecular basis in AMI.
View Article and Find Full Text PDFInvestigation of compounds as ERK5 inhibitor related to breast cancer via molecular docking and dynamic simulation.
In Silico Pharmacol
January 2025
Teady Bioscience Research Laboratory, Ilara Mokin, Ondo State Nigeria.
Unlabelled: Breast cancer remains a global health challenge, with rising cases predicted in the coming decades. The complexity of breast cancer treatment arises from its complex nature, often involving multiple therapeutic strategies. One promising approach is targeting the ERK5 pathway, a key regulator in cancer cell proliferation and survival.
View Article and Find Full Text PDFβ-Caryophyllene and Statins in Bone Fracture Healing - A Narrative Review.
Orthop Res Rev
January 2025
R&D, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.
Bone fractures are a leading cause of morbidity and healthcare expenditure globally. The complex healing process involves inflammation, cartilage formation, mineralization, and bone remodeling. Current treatments like immobilization, surgery, and bone grafting, though effective, pose significant challenges, such as prolonged recovery and high costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!